Interleukin-10 improves left ventricular function in rats with heart failure subsequent to myocardial infarction

Eur J Heart Fail. 2008 Aug;10(8):733-9. doi: 10.1016/j.ejheart.2008.06.007. Epub 2008 Jul 2.

Abstract

Evidence has shown that pro-inflammatory cytokines, especially TNF-alpha, are involved in the inflammatory response in the remodelling process after myocardial infarction (MI). Although IL-10, an anti-inflammatory cytokine, has been shown to antagonize some of the deleterious effects of TNF-alpha, little is known about its role in post-MI left ventricular (LV) dysfunction. The aim of the present study was to investigate whether a therapy with rhIL-10 could be beneficial in an animal model of post-MI heart failure (HF). Rats with experimental MI were treated with rhIL-10 (75 microg/kg/d sc) starting directly after MI induction, and continuing for 4 weeks. Controls were untreated MI and sham-operated rats. Cardiac function was assessed by echocardiography and cardiac catheterization 4 weeks after MI induction. Membrane-bound and soluble fractions of TNF-alpha, IL-6 and IL-10, the ratio of TNF-alpha to IL-10, serum levels of MCP-1 as well as myocardial macrophage infiltration, were analyzed. Treatment with rhIL-10 significantly improved post-MI LV function (FS +127%;, dP/dt(max) +131%; LVEDP -36%). This effect was associated with a significant decrease in pro-inflammatory cytokine and chemokine levels (TNF-alpha, IL-6, MCP-1) and furthermore resulted in a reduced myocardial infiltration of macrophages.

MeSH terms

  • Animals
  • Cytokines / blood
  • Echocardiography
  • Heart Failure / drug therapy*
  • Heart Failure / etiology
  • Interleukin-10 / pharmacology
  • Interleukin-10 / therapeutic use*
  • Male
  • Myocardial Infarction / complications*
  • Rats
  • Rats, Sprague-Dawley
  • Recombinant Proteins / pharmacology
  • Recombinant Proteins / therapeutic use
  • Ventricular Function, Left / drug effects*

Substances

  • Cytokines
  • Recombinant Proteins
  • Interleukin-10